3 results
Approved WMOPending
The main objective of this Phase IIa/b study is to demonstrate the effectof zibotentan on HVPG, and that dapagliflozin can mitigate fluid retention safety concernsregarding its use in this population.
Approved WMORecruiting
Main: To evaluate the efficacy of continuing SZC as part of the discharge medications, compared to SoC, in maintaining NK Secondary:To evaluate the effect of continuing SZC as part of the discharge medications, compared to SoC:1. in reducing the…
Approved WMOCompleted
· To evaluate the effect of zibotentan anddapagliflozin in combination and alone versusplacebo on UACR.